Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods to Characterize Mutant Spectra of RNA Viruses: The Case of SARS-CoV-2.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication.

Antimicrobial agents and chemotherapy·2026
Same author

SARS-CoV-2 mutant spectrum complexity is an epidemiologically evolvable trait.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Plasmacytoid and CD141+ Myeloid Dendritic Cells Cooperation with CD8+ T Cells in Lymph Nodes is Associated with HIV Control.

MedComm·2025
Same author

Metagenomic analysis of heavy water-adapted bacterial communities.

Microbial genomics·2025
Same author

SARS-CoV-2 post-acute sequelae linked to inflammation via extracellular vesicles.

Frontiers in immunology·2025

Related Experiment Video

Updated: Aug 31, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.2K

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture.

Carlos García-Crespo1,2, Lucía Vázquez-Sirvent1,3, Pilar Somovilla1,4

  • 1Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Frontiers in Microbiology
|August 22, 2022
PubMed
Summary

Antiviral drug effectiveness against hepatitis C virus decreases significantly when treatment begins after infection starts. Viral fitness and timing of administration are key factors influencing drug efficacy in cell cultures.

Keywords:
daclatasvirdelayed drug administrationdirect acting antiviralsfavipiravirlethal mutagenesisribavirinsofosbuvirviral fitness

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K

Related Experiment Videos

Last Updated: Aug 31, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.2K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K

Area of Science:

  • Virology
  • Hepatitis C Virus (HCV) Research
  • Antiviral Drug Development

Background:

  • Hepatitis C virus (HCV) poses a significant global health challenge, necessitating effective antiviral therapies.
  • Current antiviral drug effectiveness assays may not fully capture real-world treatment scenarios.
  • Understanding factors influencing antiviral efficacy is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To quantify the reduction in effectiveness of antiviral agents against HCV when administered post-infection versus at infection onset.
  • To identify key determinants influencing the decreased efficacy of antiviral agents.
  • To inform the design of more rigorous preclinical antiviral effectiveness assays.

Main Methods:

  • Cell culture models of hepatitis C virus infection were utilized.
  • Antiviral assays were performed using combinations of direct-acting antiviral agents (daclatasvir and sofosbuvir) and lethal mutagens (favipiravir and ribavirin).
  • The timing of antiviral agent administration (at infection onset vs. during ongoing infection) was a primary variable.

Main Results:

  • A significant decrease in the effectiveness of antiviral agents was observed when administered during an ongoing HCV infection compared to at the beginning.
  • The time of inhibitor administration post-infection and the replicative fitness of the virus were major determinants of this efficacy reduction.
  • This phenomenon was consistently observed with both direct-acting antiviral combinations and lethal mutagen combinations.

Conclusions:

  • The timing of antiviral agent administration is critical for determining treatment effectiveness against HCV.
  • Viral replicative fitness plays a substantial role in modulating antiviral drug efficacy.
  • Preclinical antiviral effectiveness assays should incorporate high-fitness viral populations and delayed agent administration to better predict in vivo performance.